ImageneOI is the first NSCLC genomic profiling AI tool on the Sectra Amplifier Marketplace.

CGI (TSX: GIB.A) (NYSE: GIB), one of the largest IT and business consulting companies in the world, and Tribun Health, a rising force in healthcare technology, announce their partnership with Region Sjælland in Denmark for the implementation of digital pathology solutions, CaloPix®. This strategic collaboration aims to modernize pathology services, enhancing efficiency, accuracy, and innovation in diagnostics across Region Sjælland.

Rapid NSCLC Biomarker Test already demonstrated its significant impact and clinical benefits as part of a lung cancer clinical study.

Leveraging AI-based molecular profiling from a digitized biopsy image to enable physicians to gain immediate oncology intelligence.

The ImageneOI rapid AI-based biomarker profiling platform significantly improves lung cancer patient outcomes, as demonstrated by a recently published case report.

Visionaries and Experts, Each Having Played a Historical Role in Advancing Precision Oncology Into Current Clinical Practice

A groundbreaking case report publication on the impact of rapid molecular testing on lung cancer patients

PharmaNest, a leader in high resolution quantitative Digital Pathology and Artificial Intelligence, announces today the launch new quantitative tissue panels to properly quantify tissue injury and inflammation in the context of multiple fibrotic conditions, from discovery models to clinical development. Such spatially resolved datasets can be fused with other spatially resolved biology methods.

PharmaNest, a leader in high resolution, single-fiber, quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest Ph-FCS continuous fibrosis biomarker for the quantification of the severity of fibrosis and prognostics of liver related clinical events in NASH.

World's first AI diagnostic for MSI prescreening from routine H&E slides for colorectal cancer aims to help pathologists and oncologists facilitate better access to approved immunotherapy treatments for their patients.

EMA offers endorsement for AI optimization of clinical trials. Two Owkin AI models significantly improve the discrimination accuracy for overall survival in hepatocellular carcinoma and mesothelioma. Owkin to develop on-demand prognostic scores for other indications to further reduce clinical trial failure rates

New suite of time-saving products address pathology, cytology and histology laboratory staffing shortages and storage inefficiencies.

In response to a call for tenders, Tribun Health had to undergo numerous evaluations and a rating system before joining the UniHA network in digital pathology.

PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest continuous scores for the quantification of the treatment effects of NASH therapies at the 2022 Liver Meeting® | AASLD conference

Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry

The research done by Imagene and Sheba Medical Center was recently published in 'Modern Pathology' journal.

The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) enter a strategic partnership to use artificial intelligence (AI) powered tool for the diagnosis and staging of NASH (non-Alcoholic Steatohepatitis) in patients with type 2 diabetes (T2D).

The research will be presented at the European Congress of Pathology (ECP) 2022

Mindpeak breast cancer algorithms have been seamlessly integrated into the gold-standard image management software, CaloPix 5, enhancing the pathologist's possibilities.

PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest continuous score for the quantification of the severity of fibrosis and treatment effects of NASH therapies at the 2022 International Liver Conference.

The company wins the prestigious 'Best in Klas' award

New digital pathology, quantitative image analysis and quantitative AI method for liver tissues is presented for the continuous assessment of the histological phenotype(s) of fibrosis, including severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid models, NASH rodent models, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021

Introducing CaloPix 5, the next generation of the gold standard in digital pathology.

CYPATH on Track to Lead the Way in Building the Future of Pathology

Introduction of key technology to accelerate NASH drug discovery by combining 3D disease models and automated AI-based fibrosis quantification

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and regression of Fibrosis in human in-vitro 3D NASH Spheroid models and for the automated classification of post-transplant patients in F4 Fibrosis Stage with and without Hepatocellular carcinoma (HCC) at the Liver Meeting Digital Experience 2020

By combining Deciphex's unique digital pathology solutions with Cernostics tissue systems pathology approach, the partnership aims to generate novel predictive indicators using AI.

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in pre-clinical tissues and adult NASH biopsies at the Digital International Liver CongressTM 2020

New image analysis data of tissues with FibroNest™ is presented for the continuous assessment of the severity and progression of fibrosis in Kidney and Lung preclinical models at the Fibrosis and Tissue Repair 2020 Keystone Symposium.

FibroNest image analysis tool provides the most advanced cloud-based phenotypic image analysis and translational platform for the automated quantification of fibrosis across multiple fibrotic conditions and organs for drug discovery and drug development projects.

New image analysis data of biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in both adult and pediatric cohorts at the Liver Meeting® 2019.

FibroNest cloud-based image analysis tool provides the most advanced phenotypic image analysis and translational platform for the automated quantification of fibrosis and steatosis for NASH and for other fibrotic conditions in drug discovery and drug development projects.

InvitroCue, a Singapore based provider of products and services for in vitro DMPK, in vitro toxicology and digital pathology, and TissueGnostics, a developer of image acquisition and image cytometry instruments based in Vienna, have signed a term sheet to promote an jointly offer their solutions in Singapore and other Asian countries.

Senior technical management staff from Pathology Diagnostics attended the recent DakoLink-UP Scientific Symposium held in York in June 2014. Their presence strengthened connections already in place with Dako staff, and highlighted similarities in qua

Having already established itself as one of the leaders in its industry, Pathology Diagnostics is continuing to grow from strength to strength - evolving into a formidable organisation within its market space. Wanting to showcase its employee experti

Indica Labs Advance Molecular Pathology with Multiplex RNA FISH Quantification Software

Indica Labs, inc. announce the availability of HALO, a next generation image analysis platform for digital pathology.

Indica Labs, Inc. extends its capabilities in the field of neuroscience by releasing a highly advanced image analysis software package for measuring microglial cell activation in brightfield microscopic images.

Indica Labs Unveil Groundbreaking IHC Quantification Algorithm at Pathology Visions

Indica Labs announces the official release of its advanced histology analysis software for diabetes and metabolic research

Indica Labs announces new capabilities for measuring dual ISH assays for the purpose of measuring gene amplification in tumors and other tissues.

Indica Labs, Inc. receives an initial round of seed funding to begin product development of a series of image analysis tools for digital pathology.

Future laboratories will utilize advanced diagnostic and information management technologies, and will require sophisticated and interoperable laboratory information systems.

Definiens TissueStudio™ and Definiens Developer XD Help Quantify Changes in Apoptosis in the Liver Following Chemical Exposure